-3%
Tocilizumab is used in the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Ulcerative colitis, and Crohn’s disease.
Actemra 162mg/0.9ml SC Injection contains Tocilizumab which belongs to the group of medicines called interleukin-6 (IL-6) receptor inhibitors. It is used to manage adults with moderate to severely active rheumatoid arthritis (an inflammatory disease affecting the joints).
It is also used in children aged 2 years and above to manage active systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis (inflammatory disease that causes pain and swelling in one or more joints).
Actemra 162mg/0.9ml SC Injection is also used to manage adults and children aged 2 years and over with severe cytokine release syndrome (a side-effect in patients managed with chimeric antigen receptor (CAR) T-cell therapies used to manage certain types of cancer) and to manage adults with coronavirus disease 2019 (COVID-19), receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation.
Actemra 162mg/0.9ml SC injection is not recommended in patients with active, severe infection, active liver disease, or liver impairment. It should be used with caution in patients with tuberculosis, mild to moderate kidney disease, intestinal ulcers or diverticulitis, and cancer. Consult your doctor before receiving it.
Actemra 162mg/0.9ml SC Injection is not recommended for use in pregnant women, breastfeeding mothers, and children under 2 years of age. Consult your doctor before receiving it.